EYEPOINTPHARMA.COM Stock Quote & Alerts

EYEPOINTPHARMA.COMEYEPOINTPHARMA.COM

No data available

Want to monitor EYEPOINTPHARMA.COM?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

No company information available

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance

Alerts

Key Statistics

About

News

Palantir's stock surges as AI demand drives another record quarter

Federated Hermes announces promotion of Mark Weiss to head of Prime Liquidity Group

Here's How Much Alphabet Stock Is Expected to Move After Earnings on Wednesday

Sezzle to Announce Fourth Quarter 2025 Results and Participate in Upcoming Investor Events

Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript

EverQuote to Announce Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

United States Lime & Minerals Reports Fourth Quarter and Full Year 2025 Results and Declares Regular Quarterly Cash Dividend

NXP Semiconductors Reports Fourth Quarter and Full-Year 2025 Results

MediaAlpha To Report Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026

UNIVERSAL HEALTH SERVICES, INC. ANNOUNCES DATE FOR FOURTH QUARTER 2025 EARNINGS RELEASE AND CONFERENCE CALL

AtlasClear Holdings Launches “Clearing the View,” an Ongoing Investor Communications Series

BARK Retains Moelis & Company LLC as Financial Advisor to the Special Committee

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Palantir beats fourth-quarter estimates on the strength of AI and defense demand

TeraWulf Expands Digital and Power Infrastructure Portfolio with Strategic Acquisitions in Kentucky and Maryland

Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Simon® Reports Fourth Quarter and Full Year 2025 Results

INTEGRA FILES FEASIBILITY STUDY TECHNICAL REPORT FOR DELAMAR HEAP LEACH PROJECT

CarGurus To Report Fourth Quarter and Full-Year 2025 Financial Results

Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares